Effects of converting enzyme inhibition on split renal function in renovascular hypertension.
The effects of captopril on effective renal plasma flow and glomerular filtration rate were studied using a noninvasive radioisotopic method on individual kidneys in eight patients with renovascular hypertension and 12 patients with essential hypertension with various renin levels. Four patients with renovascular hypertension had unilateral while three had bilateral renal artery stenosis. The effective renal plasma flow and glomerular filtration rate were determined by using 131I-iodohippurate sodium and 99mTc-diethylenetriamine pentaacetic acid, respectively. Glomerular filtration rate and effective renal plasma flow were significantly reduced in the stenotic kidneys of patients with renovascular hypertension compared with values in nonstenotic kidneys (p less than 0.01). Treatment with captopril, 37.5 to 75 mg/day for 1 to 48 weeks, further reduced the glomerular filtration rate only in stenotic kidneys, and effective renal plasma flow increased in both kidney types. In two of the three renal hypertensive patients with bilateral renal artery stenosis, captopril produced a reversible azotemia that was unrelated to the fall in blood pressure, as evidenced by the lack of azotemia seen after a moderate blood pressure reduction induced by other antihypertensive medications. These results indicate that endogenous angiotensin II is essential in maintaining the glomerular filtration rate in stenotic kidneys and suggest that a reduction in glomerular filtration rate during captopril administration could indicate the presence of renal artery stenosis.
D000328:Adult; D000450:Aldosterone / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril / Q000627:therapeutic use; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D006977:Hypertension, Renal / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology; D007668:Kidney / Q000098:blood supply / Q000187:drug effects*; D008875:Middle Aged; D004369:Pentetic Acid / Q000378:metabolism; D012039:Regional Blood Flow / Q000187:drug effects; D012078:Renal Artery Obstruction / Q000150:complications; D012083:Renin / Q000097:blood; D013667:Technetium / Q000378:metabolism; D016284:Technetium Tc 99m Pentetate; D010130:p-Aminohippuric Acid / Q000378:metabolism
D000806:Angiotensin-Converting Enzyme Inhibitors; D000450:Aldosterone; D013667:Technetium; D004369:Pentetic Acid; D002216:Captopril; D012083:Renin; D016284:Technetium Tc 99m Pentetate; D010130:p-Aminohippuric Acid